A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities

David B Clemow,1 Chris Bushe,2 Michele Mancini,3 Michael H Ossipov,4 Himanshu Upadhyaya1 1Eli Lilly and Company, Indianapolis, IN, USA; 2Eli Lilly, Windlesham, UK; 3Eli Lilly Italia S.p.A., Sesto Fiorentino, Italy; 4inVentiv Health Clinical, LLC, Blue Bell, PA, USA Abstract: Attention-deficit hype...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Clemow DB, Bushe C, Mancini M, Ossipov MH, Upadhyaya H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Atomoxetine attention-deficit hyperactivity disorder comorbid psychiatric disorders juvenile attention-deficit hyperactivity disorder adult attention-deficit hyperactivity disorder Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/263f729772de4a7fa846bffae8a40a3f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:263f729772de4a7fa846bffae8a40a3f
record_format	dspace
spelling	oai:doaj.org-article:263f729772de4a7fa846bffae8a40a3f2021-12-02T06:37:25ZA review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities1178-2021https://doaj.org/article/263f729772de4a7fa846bffae8a40a3f2017-02-01T00:00:00Zhttps://www.dovepress.com/a-review-of-the-efficacy-of-atomoxetine-in-the-treatment-of-attention--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021David B Clemow,1 Chris Bushe,2 Michele Mancini,3 Michael H Ossipov,4 Himanshu Upadhyaya1 1Eli Lilly and Company, Indianapolis, IN, USA; 2Eli Lilly, Windlesham, UK; 3Eli Lilly Italia S.p.A., Sesto Fiorentino, Italy; 4inVentiv Health Clinical, LLC, Blue Bell, PA, USA Abstract: Attention-deficit hyperactivity disorder (ADHD) is a common neuropsychiatric disorder that is often diagnosed during childhood, but has also increasingly been recognized to occur in adults. Importantly, up to 52% of children (including adolescents) and 87% of adults with ADHD also have a comorbid psychiatric disorder. The presence of a comorbid disorder has the potential to impact diagnosis and could affect treatment outcomes. Atomoxetine is a nonstimulant treatment for ADHD. Despite numerous published studies regarding efficacy of atomoxetine in the treatment of ADHD in patients with comorbid disorders, there is limited information about the impact of individual common comorbid disorders on the efficacy of atomoxetine for ADHD, especially with regard to adults. Moreover, a cumulative review and assessment of these studies has not been conducted. For this reason, we performed a literature review to find, identify, and cumulatively review clinical studies that examined the efficacy of atomoxetine in the treatment of patients with ADHD and comorbid psychiatric disorders. We found a total of 50 clinical studies (37 in children; 13 in adults) that examined the efficacy of atomoxetine in patients with ADHD and a comorbid disorder. The comorbidities that were studied in children or in adults included anxiety, depression, and substance use disorder. Overall, the presence of comorbidity did not adversely impact the efficacy of atomoxetine in treatment of ADHD symptoms in both patient populations. In the studies identified and assessed in this review, atomoxetine did not appear to exacerbate any of the comorbid conditions and could, therefore, be an important therapy choice for the treatment of ADHD in the presence of comorbid disorders. Keywords: comorbid psychiatric disorders, ADHD in children or adolescents, adult attention-deficit hyperactivity disorder, ADHDClemow DBBushe CMancini MOssipov MHUpadhyaya HDove Medical PressarticleAtomoxetineattention-deficit hyperactivity disordercomorbid psychiatric disordersjuvenile attention-deficit hyperactivity disorderadult attention-deficit hyperactivity disorderNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 357-371 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Atomoxetine attention-deficit hyperactivity disorder comorbid psychiatric disorders juvenile attention-deficit hyperactivity disorder adult attention-deficit hyperactivity disorder Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Atomoxetine attention-deficit hyperactivity disorder comorbid psychiatric disorders juvenile attention-deficit hyperactivity disorder adult attention-deficit hyperactivity disorder Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Clemow DB Bushe C Mancini M Ossipov MH Upadhyaya H A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities
description	David B Clemow,1 Chris Bushe,2 Michele Mancini,3 Michael H Ossipov,4 Himanshu Upadhyaya1 1Eli Lilly and Company, Indianapolis, IN, USA; 2Eli Lilly, Windlesham, UK; 3Eli Lilly Italia S.p.A., Sesto Fiorentino, Italy; 4inVentiv Health Clinical, LLC, Blue Bell, PA, USA Abstract: Attention-deficit hyperactivity disorder (ADHD) is a common neuropsychiatric disorder that is often diagnosed during childhood, but has also increasingly been recognized to occur in adults. Importantly, up to 52% of children (including adolescents) and 87% of adults with ADHD also have a comorbid psychiatric disorder. The presence of a comorbid disorder has the potential to impact diagnosis and could affect treatment outcomes. Atomoxetine is a nonstimulant treatment for ADHD. Despite numerous published studies regarding efficacy of atomoxetine in the treatment of ADHD in patients with comorbid disorders, there is limited information about the impact of individual common comorbid disorders on the efficacy of atomoxetine for ADHD, especially with regard to adults. Moreover, a cumulative review and assessment of these studies has not been conducted. For this reason, we performed a literature review to find, identify, and cumulatively review clinical studies that examined the efficacy of atomoxetine in the treatment of patients with ADHD and comorbid psychiatric disorders. We found a total of 50 clinical studies (37 in children; 13 in adults) that examined the efficacy of atomoxetine in patients with ADHD and a comorbid disorder. The comorbidities that were studied in children or in adults included anxiety, depression, and substance use disorder. Overall, the presence of comorbidity did not adversely impact the efficacy of atomoxetine in treatment of ADHD symptoms in both patient populations. In the studies identified and assessed in this review, atomoxetine did not appear to exacerbate any of the comorbid conditions and could, therefore, be an important therapy choice for the treatment of ADHD in the presence of comorbid disorders. Keywords: comorbid psychiatric disorders, ADHD in children or adolescents, adult attention-deficit hyperactivity disorder, ADHD
format	article
author	Clemow DB Bushe C Mancini M Ossipov MH Upadhyaya H
author_facet	Clemow DB Bushe C Mancini M Ossipov MH Upadhyaya H
author_sort	Clemow DB
title	A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities
title_short	A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities
title_full	A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities
title_fullStr	A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities
title_full_unstemmed	A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities
title_sort	review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/263f729772de4a7fa846bffae8a40a3f
work_keys_str_mv	AT clemowdb areviewoftheefficacyofatomoxetineinthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadultpatientswithcommoncomorbidities AT bushec areviewoftheefficacyofatomoxetineinthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadultpatientswithcommoncomorbidities AT mancinim areviewoftheefficacyofatomoxetineinthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadultpatientswithcommoncomorbidities AT ossipovmh areviewoftheefficacyofatomoxetineinthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadultpatientswithcommoncomorbidities AT upadhyayah areviewoftheefficacyofatomoxetineinthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadultpatientswithcommoncomorbidities AT clemowdb reviewoftheefficacyofatomoxetineinthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadultpatientswithcommoncomorbidities AT bushec reviewoftheefficacyofatomoxetineinthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadultpatientswithcommoncomorbidities AT mancinim reviewoftheefficacyofatomoxetineinthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadultpatientswithcommoncomorbidities AT ossipovmh reviewoftheefficacyofatomoxetineinthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadultpatientswithcommoncomorbidities AT upadhyayah reviewoftheefficacyofatomoxetineinthetreatmentofattentiondeficithyperactivitydisorderinchildrenandadultpatientswithcommoncomorbidities
_version_	1718399800475385856

A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities

Ejemplares similares